These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20171097)

  • 1. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors. Part 2: Modification of P3, P4, and P5 regions.
    Wiener JJ; Wickboldt AT; Wiener DK; Lee-Dutra A; Edwards JP; Karlsson L; Nguyen S; Sun S; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2375-8. PubMed ID: 20171097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.
    Lee-Dutra A; Wiener DK; Arienti KL; Liu J; Mani N; Ameriks MK; Axe FU; Gebauer D; Desai PJ; Nguyen S; Randal M; Thurmond RL; Sun S; Karlsson L; Edwards JP; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2370-4. PubMed ID: 20153648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thioether acetamides as P3 binding elements for tetrahydropyrido-pyrazole cathepsin S inhibitors.
    Wiener DK; Lee-Dutra A; Bembenek S; Nguyen S; Thurmond RL; Sun S; Karlsson L; Grice CA; Jones TK; Edwards JP
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2379-82. PubMed ID: 20188543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazole-based arylalkyne cathepsin S inhibitors. Part III: modification of P4 region.
    Wiener JJ; Wickboldt AT; Nguyen S; Sun S; Rynberg R; Rizzolio M; Karlsson L; Edwards JP; Grice CA
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1070-4. PubMed ID: 23313244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazole-based arylalkyne cathepsin S inhibitors. Part II: optimization of cellular potency.
    Ameriks MK; Cai H; Edwards JP; Gebauer D; Gleason E; Gu Y; Karlsson L; Nguyen S; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6135-9. PubMed ID: 19783435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
    Ameriks MK; Axe FU; Bembenek SD; Edwards JP; Gu Y; Karlsson L; Randal M; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6131-4. PubMed ID: 19773165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazole-based cathepsin S inhibitors with improved cellular potency.
    Wei J; Pio BA; Cai H; Meduna SP; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5525-8. PubMed ID: 17822900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors.
    Ameriks MK; Bembenek SD; Burdett MT; Choong IC; Edwards JP; Gebauer D; Gu Y; Karlsson L; Purkey HE; Staker BL; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4060-4. PubMed ID: 20541404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.
    Ayesa S; Lindquist C; Agback T; Benkestock K; Classon B; Henderson I; Hewitt E; Jansson K; Kallin A; Sheppard D; Samuelsson B
    Bioorg Med Chem; 2009 Feb; 17(3):1307-24. PubMed ID: 19124252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors.
    Gustin DJ; Sehon CA; Wei J; Cai H; Meduna SP; Khatuya H; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1687-91. PubMed ID: 15745822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR studies of some acetophenone phenylhydrazone based pyrazole derivatives as anticathepsin agents.
    Raghav N; Singh M
    Bioorg Chem; 2017 Dec; 75():38-49. PubMed ID: 28915464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
    Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
    Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.
    Boros EE; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Paulick MG; Shewchuk LM; Thompson JB; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3425-9. PubMed ID: 15177446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.
    Kerns JK; Nie H; Bondinell W; Widdowson KL; Yamashita DS; Rahman A; Podolin PL; Carpenter DC; Jin Q; Riflade B; Dong X; Nevins N; Keller PM; Mitchell L; Tomaszek T
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4409-15. PubMed ID: 21733692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.
    Chatterjee AK; Liu H; Tully DC; Guo J; Epple R; Russo R; Williams J; Roberts M; Tuntland T; Chang J; Gordon P; Hollenbeck T; Tumanut C; Li J; Harris JL
    Bioorg Med Chem Lett; 2007 May; 17(10):2899-903. PubMed ID: 17382545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
    Tully DC; Liu H; Chatterjee AK; Alper PB; Epple R; Williams JA; Roberts MJ; Woodmansee DH; Masick BT; Tumanut C; Li J; Spraggon G; Hornsby M; Chang J; Tuntland T; Hollenbeck T; Gordon P; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5112-7. PubMed ID: 16876402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors.
    Cai J; Baugh M; Black D; Long C; Jonathan Bennett D; Dempster M; Fradera X; Gillespie J; Andrews F; Boucharens S; Bruin J; Cameron KS; Cumming I; Hamilton W; Jones PS; Kaptein A; Kinghorn E; Maidment M; Martin I; Mitchell A; Rankovic Z; Robinson J; Scullion P; Uitdehaag JC; Vink P; Westwood P; van Zeeland M; van Berkom L; Bastiani M; Meulemans T
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4350-4. PubMed ID: 20598883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors.
    Cai J; Bennett DJ; Rankovic Z; Dempster M; Fradera X; Gillespie J; Cumming I; Finlay W; Baugh M; Boucharens S; Bruin J; Cameron KS; Hamilton W; Kerr J; Kinghorn E; McGarry G; Robinson J; Scullion P; Uitdehaag JC; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4447-50. PubMed ID: 20594841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of selective Cathepsin inhibitors.
    Bethel PA; Gerhardt S; Jones EV; Kenny PW; Karoutchi GI; Morley AD; Oldham K; Rankine N; Augustin M; Krapp S; Simader H; Steinbacher S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4622-5. PubMed ID: 19616430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.